Proteros Biostructures
Booth number: 180-18
www.proteros.com/
About us
Overview: Situated in the heart of the Martinsried/Munich Biotech Cluster in Germany and boasting a strong presence in Boston and San Diego, our company is a pioneering force in early-stage drug discovery services. We are deeply rooted in Nobel Prize-winning science from the prestigious Max-Planck Institute of Biochemistry.
Key Strengths:
Cutting-edge Discovery Engine: Our innovative discovery platform drives our success in developing novel therapeutic solutions.
Proven Track Record: We have a history of successful collaborations with leading global pharmaceutical and biotech companies, underscoring our reliability and expertise in the industry.
Strategic Position: As a significant player in the expanding drug discovery market, we are well-positioned to capitalize on growth opportunities and deliver value to our partners and clients.
Global Reach: With operational bases in major biotech hubs in both Germany and the United States, we are strategically located to serve and collaborate with a worldwide clientele, ensuring a robust and dynamic exchange of scientific innovation and business acumen.
Partnering strategy/collaborations
Orion Pharma:
Long term multi-target research partnership for drug discovery in oncology and pain
Assembly of novel high-diversity small molecule library
Library collection distinguished by novel unique design concepts based on a proprietary set of selection filters to ensure high quality and drug-likeness of individual compounds, selectively compiled from the premium chemical provider Enamine and others
Adrestia Therapeutics:
Multi-target partnership to discover first-in-class drugs for intractable genetic diseases
Provides new phase for Adrestia’s portfolio of validated synthetic rescue targets moving into drug discovery for genetically defined neurologic and cardiomyopathic diseases.
Astrazeneca’s oncology collaboration and license agreement with Proteros.
The collaboration combines Proteros’ expertise in the identification and characterization of inhibitors with novel binding mechanisms for technically challenging drug targets with AstraZeneca’s leadership in the discovery and development of oncology medicines.
Address
Bunsenstr. 7a
82152 Martinsried
Germany
E-mail: requests@proteros.de
Phone: +49 89 7007610
Internet: www.proteros.com/
Products & Services
Proteros Drug Discovery Solutions
Qualified hits to unlock challenging drug targets
Enhance your drug discovery programs with the Proteros Discovery Solutions platform delivering hits that unlock even the most technically challenging targets.
Highly successful track record
Flexible access to all the Proteros capabilities under the guidance of a Proteros project manager experienced in early drug discovery
Delivery of Qualified/Advanced Qualified Hits using our range of selected small molecule libraries. Ideal starting points for drug discovery projects.
1. Fragment Library
2. Cluster-based Library
3. Range Finder Library
4. Centroid based library
Cluster Hits qualification by hit verification/characterization, biophysical MOI identification, cellular efficacy testing (if applicable) and full structure enablement
Established enabling technology platform
De-risking of challenging targets
Comprehensive data package
Protein Sciences
Generate the RIGHT protein for the right experiment
Bespoke proteins for Structural Biology or Biochemical screening
Highly experienced team with over 20 years experience
Highly successful service
o Expert Construct Design and Gene Synthesis
o Multiple cell expression systems, to match target criteria and produce at scale:
1. E.coli
2. Yeast
3. Insect
4. Mammalian cells (transient and stable cell pools)
Advanced purification systems to ensure the highest achievable level of purity and activity:
High-quality control for delivery of fit-for-function proteins
o Bespoke Gene-to-Protein Service
o Established Gallery of Protein expression conditions
Biologics
Deliver the right antibody with accurate assembly, purity, structural and biophysical characterization and early developability assessment (non-GxP).
Experienced with a wide variety of biologics formats (bs-Ab, ms-Abs, growth factors, non-human antibody formats and antigens)
Full range of Antibody production capabilities
Analytical profiling of Antibodies
Biophysical evaluation of antibodies
Biologics-x-ray crystallization and Cryo-EM
Development of stable cell pools
X-ray Crystallography
Over 20 years of experience in delivering structural biology projects for small molecule and biologics
Successful track history based upon Nobel prize-winning science
Delivered > 6000 structures
Gallery Structures
Ø >200 relevant targets ready for Protein-Ligand-Structure determination
Ø Cost-efficient with pre-defined protein production, purification, analytics and crystallization conditions
Gene-to-Structure
Ø High-quality service from construct design to structure solution and refinement
Ø High-resolution protein-ligand-structures (PLS) or apo structures
Custom Services
Ø Initial screening, Crystal optimization or Data collection or Structure solution /refinement only
Ø Epitope Binning service
Cryo-EM
Premium cryo-EM platform technology and expertise.
Delivering valuable structural biology information for small molecules, proteins and antibody complexes
Gene-to-Structure and Gallery Structures Services
- 200 relevant targets
Membrane-bound proteins
Assays, Screening and Biophysics
Full biochemical and biophysical characterization of ligand-target interactions for even the most challenging drug discovery projects.
Bespoke assay generation or select from a gallery of >150 targets